You are here:
Home / Archives for Amsterdam Molecular Therapeutics
Parkinson’s disease [PD] is one of the most common of the neurogenerative diseases affecting 1 in 100 people over the age of 60. Approximately 1.5 million Americans currently suffer from the disease and it is estimated that 60,000 Americans are newly diagnosed each year. PD is both a chronic and progressive disease.
While the precise cause [...]
Filed under Articles · Tagged with AAV, Addex Pharmaceuticals, adeno-associated virus, Amgen, AMGN, Amicus Therapeutics, Amsterdam Molecular Therapeutics, AVGN, Avigen, BDNF, CERE-120, Ceregene, CNS Protein Therapeutics, deep brain stimulation, DEPO, Depomed, dopamine, dopaminergic neurons, FOLD, GDNF, gene therapy, GENZ, Genzyme Corporation, glutamic acid decarboxylase, Impax Pharmaceuticals, Inc., IPX066, IPXL, L-dopa, LentiVector, levodopa, MANF, MDT, Medtronic, mesencephalic astrocyte-derived neurotrophic factor, Neurogen Corporation, Neurologix, neurotrophic factors, neurturin, NLX-P101, NRGN, NRGX, Oxford BioMedica, Parkinson's disease, PRAN, Prana Biotechnology, ProSavin, SynchoMed, Synergen, Unified Parkinson’s Disease Rating Scale
